Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Revenue Recognized From Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three and six months ended June 30, 2015 and 2014:

	Three Months Ended June 30,				Six Months Ended    June 30,
	2015		2014		2015		2014
Teva:
Recognition of upfront payment	$	2,908	$	3,095	$	5,784	$	6,120
Research funding		45		87		90		167
Genentech:
Recognition of upfront payment		181		969		360		1,755
Research funding		910		1,145		1,820		2,255
Total collaboration revenue	$	4,044	$	5,296	$	8,054	$	10,297